A new study has raised concerns about the health risks of stopping widely used GLP-1 drugs—medications prescribed for diabetes and weight loss—warning that discontinuation may significantly increase the chances of heart attack, stroke, and even death.
The research, based on health records of more than 300,000 patients, found that people who stopped taking GLP-1 therapies experienced a rapid loss of cardiovascular protection. Continuous users of these drugs showed an 18% lower risk of major heart-related events compared to those on older treatments. However, stopping the medication for just six months increased cardiovascular risk by about 4%, while remaining off the drugs for two years raised the risk by as much as 22%.
GLP-1 receptor agonists—including popular drugs used to manage type 2 diabetes and obesity—are known to improve blood sugar control, promote weight loss, and reduce inflammation, all of which contribute to better heart health. But researchers say these benefits appear to depend on consistent, long-term use.
Also Read: Health Benefits of Star Fruit
Experts warn that interruptions in treatment may trigger what some describe as a “metabolic rebound,” where patients regain weight and experience worsening blood sugar and inflammation levels. These changes can quickly elevate cardiovascular risk.
Importantly, restarting the medication does not fully restore the lost benefits, suggesting that gaps in therapy could have lasting consequences.
The findings highlight the need for patients to consult doctors before stopping GLP-1 drugs and to view them as part of long-term disease management rather than short-term solutions.
Also Read: healthy returns
